Love it, but…I think the ‘months needing treatment’ multiplier is a bit exuberant?
I can’t remember where I read this (so I could be wrong) but the Japan sales figures showed a high percentage of sales coming from new users, which to me indicated a low percentage of sales coming from repeat prescriptions. Either way my impression was that the product wasn’t being used as a daily thing.
Having said that I know Japan ain’t the US and there appears to be very different sales strategies. Would love it if someone with a better memory could confirm/deny my thoughts on the Japan repeat prescription numbers.
Love it, but…I think the ‘months needing treatment’ multiplier...
-
- There are more pages in this discussion • 329 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.8¢ |
Change
-0.008(2.11%) |
Mkt cap ! $640.6M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.3¢ | 34.5¢ | $299.3K | 859.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 297096 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 219846 | 10 |
View Market Depth
| Last trade - 12.06pm 01/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |